샘플 요청 목록

 카트 문의
시장보고서
상품코드
2141869

GLP-1과 CGM 융합 시장 인사이트, 경쟁 구도 및 시장 예측(2033년)

GLP-1 and CGM Convergence Market Insights, Competitive Landscape, and Market Forecast - 2033
발행일: | 리서치사: 구분자 Fairfield Market Research | 페이지 정보: 영문 269 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



가격
Unprintable PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.
US $ 4,995 금액 안내 화살표 ￦ 6,730,000
Unprintable PDF & Excel (Multi User License upto 5 users) help
PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.
US $ 7,295 금액 안내 화살표 ￦ 9,829,000
Printable PDF & Excel (Enterprise License above 5 users) help
PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,495 금액 안내 화살표 ￦ 11,446,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

GLP-1과 CGM 융합 시장은 2033년까지 36억 5,917만 달러에 달할 것으로 예측됩니다

서론

세계 GLP-1과 CGM 융합 시장은 2026년에 6억 5,000만 달러 규모에 달할 것으로 예상되며, 2026년부터 2033년까지 연평균 성장률(CAGR) 28%를 기록하며 2033년에는 36억 5,917만 달러에 달할 것으로 전망됩니다. Fairfield Market Research는 이미 발표된 제품별, 고객별, 지역별 분류를 통해 시장을 평가하고 있습니다. 이 예측은 조사 기간 전반에 걸친 상업적 우선순위를 평가하기 위한 공통 기준을 제공합니다.

시장 인사이트

제품 유형별 분류에는 GLP-1/CGM 통합 디지털 플랫폼, GLP-1 데이터 통합 기능을 갖춘 독립형 CGM 기기 및 기타가 포함됩니다. 최종사용자별 분류에는 2형 당뇨병 환자, 체중 관리 환자(비당뇨병 환자) 및 기타가 포함됩니다. 유통 채널별 분류에는 소비자 직접 판매/원격의료 및 의료 기관/제공자에 의한 처방이 포함됩니다. 이러한 구분은 기업이 어떤 제품이나 고객 요구 사항이 시장 범위에 해당하는지 평가하는 데 도움이 됩니다. 세계 예측은 개별 카테고리에 일률적으로 적용하기보다는 이러한 부문 정의와 함께 참조하시기 바랍니다.

제품 유형 분류에서 GLP-1/CGM 통합 디지털 플랫폼과 GLP-1 데이터 통합 기능을 갖춘 독립형 CGM 기기는 본 보고서에서 별도의 범주로 취급됩니다. 이러한 카테고리를 명확히 구분해 둠으로써, 독자는 시장 전체에 대한 예측을 특정 사업 계획에 적용하기 전에 자사 제품의 적합성을 평가하기가 더 쉬워집니다.

최종사용자 분류에서 2형 당뇨병 환자와 체중 관리 환자(비당뇨병 환자)는 본 보고서에서 별도의 범주로 취급됩니다. 이러한 범주를 명확히 구분해 두면, 독자는 시장 전체의 예측을 특정 사업 계획에 적용하기 전에 제공 제품의 적합성을 평가하기가 더 쉬워집니다.

유통 채널 분류에서, 본 보고서에서는 ‘소비자 대상 직접 판매/원격의료’와 ‘임상/의료 제공자에 의한 처방’이 별도의 범주로 취급됩니다. 이러한 범주를 명확히 구분해 두면, 독자 여러분은 시장 전체의 예측을 구체적인 사업 계획에 적용하기 전에 제공 서비스의 적합성을 평가하기가 더 쉬워집니다.

촉진요인

Fairfield의 성장에 대한 인사이트에서는 GLP-1과 CGM을 통합한 디지털 플랫폼, 2형 당뇨병 환자, 그리고 소비자 직접 판매/원격의료를 다루고 있습니다. 이러한 주제는 수요 상황과 공급업체가 직면한 요건을 평가하기 위한 출발점이 됩니다. 그 상업적 중요성은 대상 부문, 고객, 지역에 따라 다릅니다. 기업은 본 보고서의 상세한 인사이트를 활용하여 이러한 수요 요인을 자사의 포트폴리오 및 판매 우선순위와 연계할 수 있습니다.

비즈니스 기회

비즈니스 기회에 대한 인사이트에서는 제품 유형, 최종사용자, 유통 채널에 초점을 맞추고 있습니다. 사업 확장을 고려 중인 기업은 이러한 분야를 자사의 기존 역량, 시장 진입 경로, 고객의 요구 사항과 비교 검토할 수 있습니다. 개별 기업에게 공개된 예측이 어느 정도 관련성이 있는지를 평가하는 데 있어, 부문 선정과 지역 내 포지셔닝은 여전히 매우 중요합니다.

GLP-1/CGM 통합 디지털 플랫폼 도입을 검토 중인 기업은 자사의 고객 요구 사항을 GLP-1 데이터 통합 기능을 갖춘 독립형 CGM 기기와 관련된 요구 사항과 비교할 수 있습니다. 이러한 비교를 통해 보다 집중된 제품 포트폴리오를 정의하고, 적절한 판매 대상을 파악하며, 자원을 투입하기 전에 어떤 부분에 대해 추가적인 부문 증거가 필요한지 명확히 할 수 있습니다.

2형 당뇨병 환자를 대상으로 하는 기업은 해당 고객 요구 사항을 체중 관리를 목적으로 하는 환자(비당뇨병 환자)와 관련된 요구 사항과 비교할 수 있습니다. 이러한 비교를 통해 보다 집중된 포트폴리오를 정의하고, 적절한 판매 대상층을 특정하며, 자원을 투입하기 전에 추가적인 부문 증거가 필요한 과제를 파악하는 데 도움이 됩니다.

지역 분석

Fairfield의 지역 분석에서는 북미가 주요 시장으로 파악되었습니다. 지리적 범위는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카를 포괄합니다. 지역 간 비교를 수행할 때는 본 보고서의 고유한 시장 정의 및 예측 기간을 사용하십시오.

목차

제1장 주요 요약

제2장 시장 개요

제3장 세계의 GLP-1과 CGM 융합 시장 전망, 2020-2033년

제4장 북미의 GLP-1과 CGM 융합 시장 전망, 2020-2033년

제5장 유럽의 GLP-1과 CGM 융합 시장 전망, 2020-2033년

제6장 아시아태평양의 GLP-1과 CGM 융합 시장 전망, 2020-2033년

제7장 라틴아메리카의 GLP-1과 CGM 융합 시장 전망, 2020-2033년

제8장 중동 및 아프리카의 GLP-1과 CGM 융합 시장 전망, 2020-2033년

제9장 경쟁 구도

제10장 부록

KSM 26.10.13

GLP-1 and CGM Convergence Market Projected to Reach US$3,659.17 Mn by 2033

Introduction

The global glp-1 and cgm convergence market is valued at US$650 Mn in 2026 and projected to reach US$3,659.17 Mn by 2033, at a CAGR of 28% during 2026-2033. Fairfield Market Research assesses the market through its published product, customer and geographical classifications. The forecast provides a common basis for evaluating commercial priorities across the study period.

Market Insights

The product type breakdown covers Integrated GLP-1/CGM Digital Platforms, Standalone CGM Devices with GLP-1 Data Integration and Others. The end user breakdown covers Individuals with Type 2 Diabetes, Weight Management Patients (Non-Diabetic) and Others. The distribution channel breakdown covers Direct-to-Consumer/Telehealth and Clinical/Provider-Prescribed. These distinctions help businesses assess which offerings and customer requirements fall within the market's scope. The global forecast should be read alongside these segment definitions rather than applied uniformly to every individual category.

Within the product type classification, Integrated GLP-1/CGM Digital Platforms and Standalone CGM Devices with GLP-1 Data Integration represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Within the end user classification, Individuals with Type 2 Diabetes and Weight Management Patients (Non-Diabetic) represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Within the distribution channel classification, Direct-to-Consumer/Telehealth and Clinical/Provider-Prescribed represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Drivers

Fairfield's growth discussion addresses integrated glp-1/cgm digital platforms, individuals with type 2 diabetes and direct-to-consumer/telehealth. These themes provide a starting point for assessing demand conditions and the requirements facing suppliers. Their commercial importance depends on the segment, customer and region concerned. Businesses can use the report's detailed discussion to connect these demand factors with their own portfolios and sales priorities.

Business Opportunity

The opportunity discussion highlights product type, end user and distribution channel. Companies evaluating expansion can compare these areas with their existing capabilities, route to market and customer needs. Segment selection and regional positioning remain central to assessing the relevance of the published forecast to an individual business.

Businesses considering Integrated GLP-1/CGM Digital Platforms can compare its customer requirements with those associated with Standalone CGM Devices with GLP-1 Data Integration. This comparison can help define a more focused portfolio, identify the appropriate sales audience and establish which questions require additional segment evidence before resources are committed.

Businesses considering Individuals with Type 2 Diabetes can compare its customer requirements with those associated with Weight Management Patients (Non-Diabetic). This comparison can help define a more focused portfolio, identify the appropriate sales audience and establish which questions require additional segment evidence before resources are committed.

Region Analysis

North America is identified in Fairfield's regional analysis as a leading market. The geographical scope covers North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Regional comparisons should use the report's own market definitions and forecast period.

Key Players

  • Dexcom, Inc.
  • Abbott Laboratories
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Medtronic plc
  • Senseonics Holdings, Inc.
  • Roche Holding AG
  • Tandem Diabetes Care, Inc.
  • Insulet Corporation
  • Signos, Inc.

Segmentation

By Product Type

  • Integrated GLP-1/CGM Digital Platforms
  • Standalone CGM Devices with GLP-1 Data Integration
  • Others

By End User

  • Individuals with Type 2 Diabetes
  • Weight Management Patients (Non-Diabetic)
  • Others

By Distribution Channel

  • Direct-to-Consumer/Telehealth
  • Clinical/Provider-Prescribed

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global GLP-1 and CGM Convergence Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 3.1. Global GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 3.1.1. Integrated GLP-1/CGM Digital Platforms
    • 3.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 3.1.3. Others
  • 3.2. Global GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 3.2.1. Individuals with Type 2 Diabetes
    • 3.2.2. Weight Management Patients (Non-Diabetic)
    • 3.2.3. Others
  • 3.3. Global GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 3.3.1. Direct-to-Consumer/Telehealth
    • 3.3.2. Clinical/Provider-Prescribed
  • 3.4. Global GLP-1 and CGM Convergence Market Outlook, by Region, Value (US$ Mn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 4.1. North America GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 4.1.1. Integrated GLP-1/CGM Digital Platforms
    • 4.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 4.1.3. Others
  • 4.2. North America GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 4.2.1. Individuals with Type 2 Diabetes
    • 4.2.2. Weight Management Patients (Non-Diabetic)
    • 4.2.3. Others
  • 4.3. North America GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 4.3.1. Direct-to-Consumer/Telehealth
    • 4.3.2. Clinical/Provider-Prescribed
  • 4.4. North America GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 4.4.1. U.S. GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 4.4.2. U.S. GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 4.4.3. U.S. GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 4.4.4. Canada GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 4.4.5. Canada GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 4.4.6. Canada GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 5.1. Europe GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 5.1.1. Integrated GLP-1/CGM Digital Platforms
    • 5.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 5.1.3. Others
  • 5.2. Europe GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 5.2.1. Individuals with Type 2 Diabetes
    • 5.2.2. Weight Management Patients (Non-Diabetic)
    • 5.2.3. Others
  • 5.3. Europe GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 5.3.1. Direct-to-Consumer/Telehealth
    • 5.3.2. Clinical/Provider-Prescribed
  • 5.4. Europe GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 5.4.1. Germany GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.2. Germany GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.3. Germany GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.4. Italy GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.5. Italy GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.6. Italy GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.7. France GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.8. France GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.9. France GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.10. U.K. GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.11. U.K. GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.12. U.K. GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.13. Spain GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.14. Spain GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.15. Spain GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.16. Russia GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.17. Russia GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.18. Russia GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.19. Rest of Europe GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.20. Rest of Europe GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.21. Rest of Europe GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 6.1.1. Integrated GLP-1/CGM Digital Platforms
    • 6.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 6.1.3. Others
  • 6.2. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 6.2.1. Individuals with Type 2 Diabetes
    • 6.2.2. Weight Management Patients (Non-Diabetic)
    • 6.2.3. Others
  • 6.3. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 6.3.1. Direct-to-Consumer/Telehealth
    • 6.3.2. Clinical/Provider-Prescribed
  • 6.4. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 6.4.1. China GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.2. China GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.3. China GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.4. Japan GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.5. Japan GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.6. Japan GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.7. South Korea GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.8. South Korea GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.9. South Korea GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.10. India GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.11. India GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.12. India GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.13. Southeast Asia GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.14. Southeast Asia GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.15. Southeast Asia GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.16. Rest of SAO GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.17. Rest of SAO GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.18. Rest of SAO GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 7.1. Latin America GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 7.1.1. Integrated GLP-1/CGM Digital Platforms
    • 7.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 7.1.3. Others
  • 7.2. Latin America GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 7.2.1. Individuals with Type 2 Diabetes
    • 7.2.2. Weight Management Patients (Non-Diabetic)
    • 7.2.3. Others
  • 7.3. Latin America GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 7.3.1. Direct-to-Consumer/Telehealth
    • 7.3.2. Clinical/Provider-Prescribed
  • 7.4. Latin America GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 7.4.1. Brazil GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.2. Brazil GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.3. Brazil GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.4. Mexico GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.5. Mexico GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.6. Mexico GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.7. Argentina GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.8. Argentina GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.9. Argentina GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.10. Rest of LATAM GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.11. Rest of LATAM GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.12. Rest of LATAM GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 8.1.1. Integrated GLP-1/CGM Digital Platforms
    • 8.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 8.1.3. Others
  • 8.2. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 8.2.1. Individuals with Type 2 Diabetes
    • 8.2.2. Weight Management Patients (Non-Diabetic)
    • 8.2.3. Others
  • 8.3. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 8.3.1. Direct-to-Consumer/Telehealth
    • 8.3.2. Clinical/Provider-Prescribed
  • 8.4. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 8.4.1. GCC GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.2. GCC GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.3. GCC GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.4. South Africa GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.5. South Africa GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.6. South Africa GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.7. Egypt GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.8. Egypt GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.9. Egypt GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.10. Nigeria GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.11. Nigeria GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.12. Nigeria GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.13. Rest of Middle East GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.14. Rest of Middle East GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.15. Rest of Middle East GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Dexcom, Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Abbott Laboratories
    • 9.4.3. Novo Nordisk A/S
    • 9.4.4. Eli Lilly and Company
    • 9.4.5. Medtronic plc
    • 9.4.6. Senseonics Holdings, Inc.
    • 9.4.7. Roche Holding AG
    • 9.4.8. Tandem Diabetes Care, Inc.
    • 9.4.9. Insulet Corporation
    • 9.4.10. Signos, Inc.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기